Loading…
Oral delivery of a renin inhibitor compound using emulsion formulations
The oral delivery of O-(N-morpholino-carbonyl-3-L-phenylaspartyl-L- leucinamide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylhetane (I), a new renin inhibitor, was studied in the in vivo rat model using emulsion formulations. The components of the emulsion formulations were chosen based...
Saved in:
Published in: | Pharmaceutical research 1992-07, Vol.9 (7), p.888-893 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c252t-865f1777e99dccdb2d55e2ad83454ecc385fe4468d1188c3398ebf49c83e1df33 |
---|---|
cites | |
container_end_page | 893 |
container_issue | 7 |
container_start_page | 888 |
container_title | Pharmaceutical research |
container_volume | 9 |
creator | Kararli, T T Needham, T E Griffin, M Schoenhard, G Ferro, L J Alcorn, L |
description | The oral delivery of O-(N-morpholino-carbonyl-3-L-phenylaspartyl-L- leucinamide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylhetane (I), a new renin inhibitor, was studied in the in vivo rat model using emulsion formulations. The components of the emulsion formulations were chosen based on their proposed effects on membrane structure, membrane fluidity, and solute transport. The percent absolute bioavailability (%AB) of I was increased from 0.3% (water suspension) to 5.1% when long-chain unsaturated fatty acid (oleic acid, linoleic acid, etc.)- and mono- and diglyceride (monolein, dilaurin, etc.)-containing emulsion formulations were used. Considering very high first-pass liver extraction of the compound (80%), it is suggested that emulsion formulations increased the intestinal transport of the compound significantly. The solubility of I in aqueous media with and without bile salt (20 mM) was found to be low (approximately 1 micrograms/ml). Incubation in 0.01 N HCl did not affect the particle size of the emulsion. The titration of oleic acid/monoolein emulsion in a pH 6.5 medium with a mixed bile salt system indicated reduction in the particle size of the emulsion. Drug precipitation was observed above 30 mM bile salt concentrations. No drug crystals could be detected in the intestinal contents of the rats when emulsion formulations were ingested. These results suggest that in the intestine of the animals, the particle size of the emulsions is reduced in the presence of bile fluid while the drug resides primarily in the oil phase. The mechanism of enhanced transport of I from the emulsion formulations is discussed along with the possibility of cotransport for the drug and oil. Emulsion formulations can be a potential delivery form for low-bioavailable lipid-soluble drugs. |
doi_str_mv | 10.1023/A:1015896731545 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_73333925</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73333925</sourcerecordid><originalsourceid>FETCH-LOGICAL-c252t-865f1777e99dccdb2d55e2ad83454ecc385fe4468d1188c3398ebf49c83e1df33</originalsourceid><addsrcrecordid>eNotj79LAzEcxTMotVZnJyGT22l-NolbKVqFQhedj1zyjUbukprcCf73Hti3vM_w4cFD6IaSe0oYf9g8UkKlNmvFqRTyDC2JYqLRStALdFnrFyFEUyMWaEEF14SwJdodiu2xhz7-QPnFOWCLC6SYcEyfsYtjLtjl4Zin5PFUY_rAMEx9jTnhkMuMdpy5XqHzYPsK16deoffnp7ftS7M_7F63m33jmGRjo9cyUKUUGOOd8x3zUgKzXnMhBTjHtQwgxFp7SrV2nBsNXRDGaQ7UB85X6O5_91jy9wR1bIdYHfS9TZCn2io-xzA5i7cnceoG8O2xxMGW3_b0nP8BwMxZVg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73333925</pqid></control><display><type>article</type><title>Oral delivery of a renin inhibitor compound using emulsion formulations</title><source>SpringerLink Online Journals Archive Complete</source><creator>Kararli, T T ; Needham, T E ; Griffin, M ; Schoenhard, G ; Ferro, L J ; Alcorn, L</creator><creatorcontrib>Kararli, T T ; Needham, T E ; Griffin, M ; Schoenhard, G ; Ferro, L J ; Alcorn, L</creatorcontrib><description>The oral delivery of O-(N-morpholino-carbonyl-3-L-phenylaspartyl-L- leucinamide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylhetane (I), a new renin inhibitor, was studied in the in vivo rat model using emulsion formulations. The components of the emulsion formulations were chosen based on their proposed effects on membrane structure, membrane fluidity, and solute transport. The percent absolute bioavailability (%AB) of I was increased from 0.3% (water suspension) to 5.1% when long-chain unsaturated fatty acid (oleic acid, linoleic acid, etc.)- and mono- and diglyceride (monolein, dilaurin, etc.)-containing emulsion formulations were used. Considering very high first-pass liver extraction of the compound (80%), it is suggested that emulsion formulations increased the intestinal transport of the compound significantly. The solubility of I in aqueous media with and without bile salt (20 mM) was found to be low (approximately 1 micrograms/ml). Incubation in 0.01 N HCl did not affect the particle size of the emulsion. The titration of oleic acid/monoolein emulsion in a pH 6.5 medium with a mixed bile salt system indicated reduction in the particle size of the emulsion. Drug precipitation was observed above 30 mM bile salt concentrations. No drug crystals could be detected in the intestinal contents of the rats when emulsion formulations were ingested. These results suggest that in the intestine of the animals, the particle size of the emulsions is reduced in the presence of bile fluid while the drug resides primarily in the oil phase. The mechanism of enhanced transport of I from the emulsion formulations is discussed along with the possibility of cotransport for the drug and oil. Emulsion formulations can be a potential delivery form for low-bioavailable lipid-soluble drugs.</description><identifier>ISSN: 0724-8741</identifier><identifier>DOI: 10.1023/A:1015896731545</identifier><identifier>PMID: 1438002</identifier><language>eng</language><publisher>United States</publisher><subject>Absorption - drug effects ; Administration, Oral ; Animals ; Bile Acids and Salts - pharmacology ; Chemistry, Pharmaceutical - methods ; Dipeptides - administration & dosage ; Dipeptides - pharmacokinetics ; Emulsions ; Glycerides - pharmacology ; Intestinal Mucosa - metabolism ; Male ; Morpholines - administration & dosage ; Morpholines - pharmacokinetics ; Mouth - metabolism ; Oleic Acid ; Oleic Acids - pharmacology ; Rats ; Rats, Sprague-Dawley ; Renin - antagonists & inhibitors ; Solubility</subject><ispartof>Pharmaceutical research, 1992-07, Vol.9 (7), p.888-893</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c252t-865f1777e99dccdb2d55e2ad83454ecc385fe4468d1188c3398ebf49c83e1df33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1438002$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kararli, T T</creatorcontrib><creatorcontrib>Needham, T E</creatorcontrib><creatorcontrib>Griffin, M</creatorcontrib><creatorcontrib>Schoenhard, G</creatorcontrib><creatorcontrib>Ferro, L J</creatorcontrib><creatorcontrib>Alcorn, L</creatorcontrib><title>Oral delivery of a renin inhibitor compound using emulsion formulations</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><description>The oral delivery of O-(N-morpholino-carbonyl-3-L-phenylaspartyl-L- leucinamide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylhetane (I), a new renin inhibitor, was studied in the in vivo rat model using emulsion formulations. The components of the emulsion formulations were chosen based on their proposed effects on membrane structure, membrane fluidity, and solute transport. The percent absolute bioavailability (%AB) of I was increased from 0.3% (water suspension) to 5.1% when long-chain unsaturated fatty acid (oleic acid, linoleic acid, etc.)- and mono- and diglyceride (monolein, dilaurin, etc.)-containing emulsion formulations were used. Considering very high first-pass liver extraction of the compound (80%), it is suggested that emulsion formulations increased the intestinal transport of the compound significantly. The solubility of I in aqueous media with and without bile salt (20 mM) was found to be low (approximately 1 micrograms/ml). Incubation in 0.01 N HCl did not affect the particle size of the emulsion. The titration of oleic acid/monoolein emulsion in a pH 6.5 medium with a mixed bile salt system indicated reduction in the particle size of the emulsion. Drug precipitation was observed above 30 mM bile salt concentrations. No drug crystals could be detected in the intestinal contents of the rats when emulsion formulations were ingested. These results suggest that in the intestine of the animals, the particle size of the emulsions is reduced in the presence of bile fluid while the drug resides primarily in the oil phase. The mechanism of enhanced transport of I from the emulsion formulations is discussed along with the possibility of cotransport for the drug and oil. Emulsion formulations can be a potential delivery form for low-bioavailable lipid-soluble drugs.</description><subject>Absorption - drug effects</subject><subject>Administration, Oral</subject><subject>Animals</subject><subject>Bile Acids and Salts - pharmacology</subject><subject>Chemistry, Pharmaceutical - methods</subject><subject>Dipeptides - administration & dosage</subject><subject>Dipeptides - pharmacokinetics</subject><subject>Emulsions</subject><subject>Glycerides - pharmacology</subject><subject>Intestinal Mucosa - metabolism</subject><subject>Male</subject><subject>Morpholines - administration & dosage</subject><subject>Morpholines - pharmacokinetics</subject><subject>Mouth - metabolism</subject><subject>Oleic Acid</subject><subject>Oleic Acids - pharmacology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Renin - antagonists & inhibitors</subject><subject>Solubility</subject><issn>0724-8741</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><recordid>eNotj79LAzEcxTMotVZnJyGT22l-NolbKVqFQhedj1zyjUbukprcCf73Hti3vM_w4cFD6IaSe0oYf9g8UkKlNmvFqRTyDC2JYqLRStALdFnrFyFEUyMWaEEF14SwJdodiu2xhz7-QPnFOWCLC6SYcEyfsYtjLtjl4Zin5PFUY_rAMEx9jTnhkMuMdpy5XqHzYPsK16deoffnp7ftS7M_7F63m33jmGRjo9cyUKUUGOOd8x3zUgKzXnMhBTjHtQwgxFp7SrV2nBsNXRDGaQ7UB85X6O5_91jy9wR1bIdYHfS9TZCn2io-xzA5i7cnceoG8O2xxMGW3_b0nP8BwMxZVg</recordid><startdate>19920701</startdate><enddate>19920701</enddate><creator>Kararli, T T</creator><creator>Needham, T E</creator><creator>Griffin, M</creator><creator>Schoenhard, G</creator><creator>Ferro, L J</creator><creator>Alcorn, L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19920701</creationdate><title>Oral delivery of a renin inhibitor compound using emulsion formulations</title><author>Kararli, T T ; Needham, T E ; Griffin, M ; Schoenhard, G ; Ferro, L J ; Alcorn, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c252t-865f1777e99dccdb2d55e2ad83454ecc385fe4468d1188c3398ebf49c83e1df33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Absorption - drug effects</topic><topic>Administration, Oral</topic><topic>Animals</topic><topic>Bile Acids and Salts - pharmacology</topic><topic>Chemistry, Pharmaceutical - methods</topic><topic>Dipeptides - administration & dosage</topic><topic>Dipeptides - pharmacokinetics</topic><topic>Emulsions</topic><topic>Glycerides - pharmacology</topic><topic>Intestinal Mucosa - metabolism</topic><topic>Male</topic><topic>Morpholines - administration & dosage</topic><topic>Morpholines - pharmacokinetics</topic><topic>Mouth - metabolism</topic><topic>Oleic Acid</topic><topic>Oleic Acids - pharmacology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Renin - antagonists & inhibitors</topic><topic>Solubility</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kararli, T T</creatorcontrib><creatorcontrib>Needham, T E</creatorcontrib><creatorcontrib>Griffin, M</creatorcontrib><creatorcontrib>Schoenhard, G</creatorcontrib><creatorcontrib>Ferro, L J</creatorcontrib><creatorcontrib>Alcorn, L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kararli, T T</au><au>Needham, T E</au><au>Griffin, M</au><au>Schoenhard, G</au><au>Ferro, L J</au><au>Alcorn, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral delivery of a renin inhibitor compound using emulsion formulations</atitle><jtitle>Pharmaceutical research</jtitle><addtitle>Pharm Res</addtitle><date>1992-07-01</date><risdate>1992</risdate><volume>9</volume><issue>7</issue><spage>888</spage><epage>893</epage><pages>888-893</pages><issn>0724-8741</issn><abstract>The oral delivery of O-(N-morpholino-carbonyl-3-L-phenylaspartyl-L- leucinamide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylhetane (I), a new renin inhibitor, was studied in the in vivo rat model using emulsion formulations. The components of the emulsion formulations were chosen based on their proposed effects on membrane structure, membrane fluidity, and solute transport. The percent absolute bioavailability (%AB) of I was increased from 0.3% (water suspension) to 5.1% when long-chain unsaturated fatty acid (oleic acid, linoleic acid, etc.)- and mono- and diglyceride (monolein, dilaurin, etc.)-containing emulsion formulations were used. Considering very high first-pass liver extraction of the compound (80%), it is suggested that emulsion formulations increased the intestinal transport of the compound significantly. The solubility of I in aqueous media with and without bile salt (20 mM) was found to be low (approximately 1 micrograms/ml). Incubation in 0.01 N HCl did not affect the particle size of the emulsion. The titration of oleic acid/monoolein emulsion in a pH 6.5 medium with a mixed bile salt system indicated reduction in the particle size of the emulsion. Drug precipitation was observed above 30 mM bile salt concentrations. No drug crystals could be detected in the intestinal contents of the rats when emulsion formulations were ingested. These results suggest that in the intestine of the animals, the particle size of the emulsions is reduced in the presence of bile fluid while the drug resides primarily in the oil phase. The mechanism of enhanced transport of I from the emulsion formulations is discussed along with the possibility of cotransport for the drug and oil. Emulsion formulations can be a potential delivery form for low-bioavailable lipid-soluble drugs.</abstract><cop>United States</cop><pmid>1438002</pmid><doi>10.1023/A:1015896731545</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0724-8741 |
ispartof | Pharmaceutical research, 1992-07, Vol.9 (7), p.888-893 |
issn | 0724-8741 |
language | eng |
recordid | cdi_proquest_miscellaneous_73333925 |
source | SpringerLink Online Journals Archive Complete |
subjects | Absorption - drug effects Administration, Oral Animals Bile Acids and Salts - pharmacology Chemistry, Pharmaceutical - methods Dipeptides - administration & dosage Dipeptides - pharmacokinetics Emulsions Glycerides - pharmacology Intestinal Mucosa - metabolism Male Morpholines - administration & dosage Morpholines - pharmacokinetics Mouth - metabolism Oleic Acid Oleic Acids - pharmacology Rats Rats, Sprague-Dawley Renin - antagonists & inhibitors Solubility |
title | Oral delivery of a renin inhibitor compound using emulsion formulations |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T20%3A28%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20delivery%20of%20a%20renin%20inhibitor%20compound%20using%20emulsion%20formulations&rft.jtitle=Pharmaceutical%20research&rft.au=Kararli,%20T%20T&rft.date=1992-07-01&rft.volume=9&rft.issue=7&rft.spage=888&rft.epage=893&rft.pages=888-893&rft.issn=0724-8741&rft_id=info:doi/10.1023/A:1015896731545&rft_dat=%3Cproquest_pubme%3E73333925%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c252t-865f1777e99dccdb2d55e2ad83454ecc385fe4468d1188c3398ebf49c83e1df33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73333925&rft_id=info:pmid/1438002&rfr_iscdi=true |